Arbutus Biopharma Corporation develops therapeutics for chronic Hepatitis B virus, SARS-CoV-2, and other coronaviruses. Its pipeline includes RNA interference and oral capsid inhibitor products for HBV, as well as oral HBV RNA destabilizers and PD-L1 inhibitors. The company has strategic alliances and research collaborations with various organizations. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.